

## AMENDMENTS TO THE CLAIMS

11. (Cancelled)

Sub E1  
12. (Currently Amended) The A stable lyophilized pharmaceutical composition comprising approximately 1 to 4 milligrams per milliliter of a wild type human IL-2 mutein and a stabilizing mixture comprising histidine, glycine, and sucrose, wherein said human IL-2 mutein composition of claim 1, wherein the IL-2 mutein consists of the amino acid sequence of wild-type human IL-2 with one substitution consisting of the replacement of the amino acid asparagine at position 88 in the wild-type human IL-2 with the amino acid arginine.

13. (Currently Amended) The stable lyophilized composition of claim 1-12, wherein the histidine is present at approximately 0.06 -1.8 % measured by weight.

14. (Currently Amended) The stable lyophilized composition of claim 1-12, wherein the glycine is present at approximately 1-3 % measured by weight.

15. (Currently Amended) The stable lyophilized composition of claim 1-12, wherein the sucrose is present at approximately 0.5-3 % measured by weight.

16. (Currently Amended) The stable lyophilized composition of claim 1-12 in aqueous form having a pH ranging from about 5.0 to 6.5.

17. (Currently Amended) A stable lyophilized pharmaceutical composition, which upon aqueous reconstitution comprises the following:

1.0 - 4.0 mg/ml of a human IL-2 mutein consisting of the amino acid sequence of wild-type human IL-2 with one substitution consisting of the replacement of the amino acid asparagine at position 88 in the wild-type human IL-2 with the amino acid arginine

IL-2 (N88R) 0.1 - 5.0 mg/ml,

and

Histidine 0.08 - 1.6 % wt,  
NaCl 0 - 0.9 wt %  
Sucrose 1 - 10 % wt, and  
Glycine 0 - 3% wt at a  
pH of 5 - 6.5 .